Literature DB >> 20683255

Metabolic profiling of hearts exposed to sevoflurane and propofol reveals distinct regulation of fatty acid and glucose oxidation: CD36 and pyruvate dehydrogenase as key regulators in anesthetic-induced fuel shift.

Lianguo Wang1, Kerry W S Ko, Eliana Lucchinetti, Liyan Zhang, Heinz Troxler, Martin Hersberger, Mohamed A Omar, Elena I Posse de Chaves, Gary D Lopaschuk, Alexander S Clanachan, Michael Zaugg.   

Abstract

BACKGROUND: Myocardial energy metabolism is a strong predictor of postoperative cardiac function. This study profiled the metabolites and metabolic changes in the myocardium exposed to sevoflurane, propofol, and Intralipid and investigated the underlying molecular mechanisms.
METHODS: Sevoflurane (2 vol%) and propofol (10 and 100 microM) in the formulation of 1% Diprivan (AstraZeneca Inc., Mississauga, ON, Canada) were compared for their effects on oxidative energy metabolism and contractility in the isolated working rat heart model. Intralipid served as a control. Substrate flux through the major pathways for adenosine triphosphate generation in the heart, that is, fatty acid and glucose oxidation, was measured using [H]palmitate and [C]glucose. Biochemical analyses of nucleotides, acyl-CoAs, ceramides, and 32 acylcarnitine species were used to profile individual metabolites. Lipid rafts were isolated and used for Western blotting of the plasma membrane transporters CD36 and glucose transporter 4.
RESULTS: Metabolic profiling of the hearts exposed to sevoflurane and propofol revealed distinct regulation of fatty acid and glucose oxidation. Sevoflurane selectively decreased fatty acid oxidation, which was closely related to a marked reduction in left ventricular work. In contrast, propofol at 100 microM but not 10 microM increased glucose oxidation without affecting cardiac work. Sevoflurane decreased fatty acid transporter CD36 in lipid rafts/caveolae, whereas high propofol increased pyruvate dehydrogenase activity without affecting glucose transporter 4, providing mechanisms for the fuel shifts in energy metabolism. Propofol increased ceramide formation, and Intralipid increased hydroxy acylcarnitine species.
CONCLUSIONS: Anesthetics and their solvents elicit distinct metabolic profiles in the myocardium, which may have clinical implications for the already jeopardized diseased heart.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20683255     DOI: 10.1097/ALN.0b013e3181e2c1a1

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  11 in total

1.  Anesthesia and bariatric surgery gut preparation alter plasma acylcarnitines reflective of mitochondrial fat and branched-chain amino acid oxidation.

Authors:  Sudeepa Bhattacharyya; Mohamed Ali; William H Smith; Paul E Minkler; Maria S Stoll; Charles L Hoppel; Sean H Adams
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-08-22       Impact factor: 4.310

2.  Propofol compared with isoflurane inhibits mitochondrial metabolism in immature swine cerebral cortex.

Authors:  Masaki Kajimoto; Douglas B Atkinson; Dolena R Ledee; Ernst-Bernhard Kayser; Phil G Morgan; Margaret M Sedensky; Nancy G Isern; Christine Des Rosiers; Michael A Portman
Journal:  J Cereb Blood Flow Metab       Date:  2014-01-08       Impact factor: 6.200

3.  Roles of pyruvate dehydrogenase and branched-chain α-keto acid dehydrogenase in branched-chain membrane fatty acid levels and associated functions in Staphylococcus aureus.

Authors:  Vineet K Singh; Sirisha Sirobhushanam; Robert P Ring; Saumya Singh; Craig Gatto; Brian J Wilkinson
Journal:  J Med Microbiol       Date:  2018-03-02       Impact factor: 2.472

4.  Caveolae and propofol effects on airway smooth muscle.

Authors:  K J Grim; A J Abcejo; A Barnes; V Sathish; D F Smelter; G C Ford; M A Thompson; Y S Prakash; C M Pabelick
Journal:  Br J Anaesth       Date:  2012-04-27       Impact factor: 9.166

5.  Early mitochondrial dysfunction in glycolytic muscle, but not oxidative muscle, of the fructose-fed insulin-resistant rat.

Authors:  Blair E Warren; Phing-How Lou; Eliana Lucchinetti; Liyan Zhang; Alexander S Clanachan; Andreas Affolter; Martin Hersberger; Michael Zaugg; Hélène Lemieux
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-01-14       Impact factor: 4.310

6.  Loss of Intralipid®- but not sevoflurane-mediated cardioprotection in early type-2 diabetic hearts of fructose-fed rats: importance of ROS signaling.

Authors:  Phing-How Lou; Eliana Lucchinetti; Liyan Zhang; Andreas Affolter; Manoj Gandhi; Martin Hersberger; Blair E Warren; Hélène Lemieux; Hany F Sobhi; Alexander S Clanachan; Michael Zaugg
Journal:  PLoS One       Date:  2014-08-15       Impact factor: 3.240

Review 7.  Myocyte membrane and microdomain modifications in diabetes: determinants of ischemic tolerance and cardioprotection.

Authors:  Jake Russell; Eugene F Du Toit; Jason N Peart; Hemal H Patel; John P Headrick
Journal:  Cardiovasc Diabetol       Date:  2017-12-04       Impact factor: 9.951

Review 8.  Diabetes, perioperative ischaemia and volatile anaesthetics: consequences of derangements in myocardial substrate metabolism.

Authors:  Charissa E van den Brom; Carolien Se Bulte; Stephan A Loer; R Arthur Bouwman; Christa Boer
Journal:  Cardiovasc Diabetol       Date:  2013-03-04       Impact factor: 9.951

9.  Effects of Glucose Concentration on Propofol Cardioprotection against Myocardial Ischemia Reperfusion Injury in Isolated Rat Hearts.

Authors:  Xinhua Yao; Yalan Li; Mingzhe Tao; Shuang Wang; Liangqing Zhang; Jiefu Lin; Zhengyuan Xia; Hui-Min Liu
Journal:  J Diabetes Res       Date:  2015-09-28       Impact factor: 4.011

10.  The mechanism of Intralipid®-mediated cardioprotection complex IV inhibition by the active metabolite, palmitoylcarnitine, generates reactive oxygen species and activates reperfusion injury salvage kinases.

Authors:  Phing-How Lou; Eliana Lucchinetti; Liyan Zhang; Andreas Affolter; Marcus C Schaub; Manoj Gandhi; Martin Hersberger; Blair E Warren; Hélène Lemieux; Hany F Sobhi; Alexander S Clanachan; Michael Zaugg
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.